NutriLeads’ clinical trial demonstrates that daily intake of BeniCaros helps support protective innate immune responses

Pivotal study published in Nutrients showing that Nutrileads’ proprietary carrot-derived rhamnogalacturonan-I (cRG-I) (commercially known as BeniCaros) fiber, accelerates protective anti-viral immune responses and reduces symptoms after an experimental infection with common cold virus in humans.

20 January 2022, Wageningen, the Netherlands. Dutch health ingredients company, NutriLeads, announced the publication of the positive results of a pivotal clinical trial demonstrating that its award-winning ingredient cRG-I, commercially known as Benicaros, helps support protective immune responses to a common respiratory infection.      

The Dietary Intake of Carrot-Derived Rhamnogalacturonan-I Accelerates and Augments the Innate Immune and Anti-Viral Interferon Response to Rhinovirus Infection and Reduces Duration and Severity of Symptoms in Humans in a Randomized Trial” has been published in the open access journal Nutrients1.

Conducted in collaboration with the Amsterdam University Medical Centre (UMC; location AMC), NIZO Food Research, and StatistiCal B.V. in the Netherlands, the BeniCaros clinical trial assessed how the food ingredient carrot-derived rhamnogalacturonan-I (cRG-I) impacted peoples’ responses to an experimentally induced mild rhinovirus infection. Rhinoviruses are responsible for common colds and impose an enormous economic burden on society. In the randomized, double-blind, placebo-controlled trial, 146 healthy adults were given either cRG-I or the placebo for eight weeks, after which they were exposed to a standardized dose of an attenuated rhinovirus via the nose. In the clinical study, daily consumption of BeniCaros prior to the rhinovirus infection significantly accelerated protective innate immune and antiviral responses, resulting in a 20% reduction in severity of symptoms, and a 25% reduction in symptom duration. 

René Lutter, PhD, Principal Investigator at the Amsterdam UMC, who runs the rhinovirus challenge model in collaboration with NIZO, commented: “The impact of cRG-I on the immune response observed in this nutritional intervention study is the biggest that I have ever seen with this model. It is clinically relevant and especially exciting because fast innate antiviral and immune responses are important for limiting infections with respiratory viruses.” 

The ingredient cRG-I is a unique polysaccharide upcycled from carrot pomace, a by-product of carrot juice production. It has been developed as a natural food ingredient to promote healthy immune function as previously shown2. BeniCaros was launched for formulation in dietary supplements and functional food and beverages in the US in October 2021. 

Commenting on the publication and impact of the findings, Ruud Albers, PhD, CSO of NutriLeads, said: “This publication is the culmination of extensive work by numerous people over ten years, and I am grateful to all involved for their dedication. The unique design of this trial was essential to demonstrate that consumption of cRG-I as a dietary supplement accelerated protective anti-viral immune responses, reducing the symptoms triggered by a standardized infection with a common cold virus. With increasing awareness of immune health over the past years, the discovery that cRG-I trains the immune system to respond faster when needed, is timely and particularly relevant.  

These exciting results fully support our earlier findings with cRG-I2 and play an important role in supporting the launch of BeniCaros (cRG-I) our immune health ingredient. This publication is a significant milestone for the company as we progress in our mission to unlock the potential of clinically proven food ingredients”. 

References
1. https://www.mdpi.com/2072-6643/13/12/4395

2. https://www.mdpi.com/2072-6643/13/3/963

Share

NutriLeads launches clinically backed BeniCaros™ for sustainable, year-round immune support

October 1, 2021, Wageningen, The Netherlands – Dutch health ingredients company, NutriLeads, announced the launch of its proprietary immune health ingredient, BeniCaros™. Upcycled from carrot pomace, BeniCaros is developed for supplements and functional food & beverages, and it is clinically supported to help to prepare your immune system to be fit all year round.

NutriLead’s proprietary extraction process unlocks rhamnogalacturonan-I (RG-I), the polysaccharide that gives BeniCaros its potential to deliver a dual mechanism of immune support. BeniCaros and its benefits are based on many years of robust pre-clinical and clinical research providing evidence that daily consumption of BeniCaros prepares the healthy immune system to function at its best when it matters most. As little as 0.3 grams per day was shown to be effective in a pivotal clinical trial. BeniCaros works by supporting the immune system to become more responsive to potential threats and challenges while also stimulating beneficial gut microorganisms and their metabolites, which in turn support immune responses.

“I have been active in this field for more than 25-years and have never seen another ingredient with such distinctive data supporting its effectiveness. Our main clinical trial demonstrates unique and very consistent effects of BeniCaros,” said Dr. Ruud Albers, CSO of Nutrileads. “There are many immune health ingredient options out there, but very few that work like BeniCaros and even fewer that work with the same efficacy to support immune function. At a time when demand has surged for immune health solutions, we see BeniCaros as a clear and unique way to improve health and wellness.”

BeniCaros is a soluble fiber made using a proprietary process by upcycling carrot pomace, a side stream of carrot juice production. It is a sustainably produced, tasteless and odorless powder that does not use artificial additives, making it a very label friendly ingredient. BeniCaros can be formulated into most functional food, beverage and supplement formats and meets consumer demands for a sustainable, clean ingredient that makes a difference.

“Having worked with the NutriLeads team on the development of BeniCaros since 2015, I am thrilled that we can now launch BeniCaros and make its benefits available to consumers together with our partners, the food & beverage and supplement companies,” said Erik Dam, CEO of NutriLeads. “There is no better way to get these benefits. While you can eat carrots, and RG-I is a natural component of carrots, it requires our proprietary technology to fully unlock RG-I from the carrot and make it available in the gut where it can do its work. BeniCaros delivers superior benefits for optimal health outcomes at a time when consumers want and need it most.”

NutriLeads has signed its first agreements and is currently in further discussions with other food companies and supplement manufacturers to incorporate BeniCaros into dietary supplements and functional food and beverage products.

Learn more about NutriLeads and BeniCaros by meeting Erik Dam, Ruud Albers and the NutriLeads team at stand #H70E at VitaFoods Europe, booth #5531 at SupplySide West, stand #30L81 at FI Food Ingredients in Germany.

About NutriLeads

Established in 2012, NutriLeads is a Health Ingredients company advancing nutrition to strengthen human health. Based on our proprietary RG-I platform, we are developing a portfolio of natural, plant-based ingredients that are clinically proven to support human physiology and modulate the gut microbiome. The Company’s first commercially available RG-I-based ingredient, BeniCaros, supports immune function. The ingredient, which is extracted from carrots, is developed for the formulation of dietary supplements and functional foods. The Company is headquartered in Wageningen, the Netherlands, a world-renowned center for nutrition and health research and development, also known as the ‘Food valley’.

Share

Nutrileads appoints Erik Dam as CEO to propel the company towards successful commercialization of its lead ingredient BeniCaros

3 June, 2021

Dutch health ingredients innovator, NutriLeads, announces the appointment of Erik Dam as CEO to lead the company’s transition from a health ingredients innovator to a commercial health ingredients company based on a strong science foundation.
Erik Dam has been appointed as CEO as of June 1st, 2021. The leadership team will further consist of Ruud Albers (CSO), Annick Mercenier (CIO) and Jan Jongsma (COO).

To put this change in context of Nutrileads’ successful development, Ruud Albers explains: “Since founding Nutrileads with Erik and Annick, I combined the roles of CEO and CSO. I am delighted that we have now reached the time for Erik, who has been the CBO and CFO since 2014, to take over as CEO. With his background in marketing and general management, I am convinced that Erik will catalyze the further evolution of Nutrileads from a R&D-driven organization to a company that develops, produces and sells clinically proven health ingredients. Together with Annick and the rest of the R&D team, I will continue to follow my passion and focus on the exciting science behind our unique ingredients, supporting production and sales to bring substantiated health benefits to consumers.”

Prior to joining Nutrileads as co-founder in 2014, Erik started his career at Andersen Consulting before entering the life sciences industry in 1993 at Baxter where he held international marketing and general management roles. In 2005 Erik joined the Medical Nutrition division of Numico/Danone where he held global VP roles in strategy and general management. He started his own consultancy company in 2013 with a focus on commercialising Nutrition & Life Sciences innovations.

”The last 7 years at NutriLeads have been an exciting journey and we have accomplished a lot with the team under the leadership of Ruud. I’m thrilled to lead the next phase during which we will establish NutriLeads as a commercial health ingredient company with leading ingredient brands starting with BeniCaros for immune health,” Erik adds.

Sanne Melles, chairman of the supervisory board of NutriLeads comments: “The board is thankful for Ruud Albers’ leadership of NutriLeads since its establishment and wishes Erik Dam all the best in his new role aimed at transforming NutriLeads into a health ingredient company and driving the business forward.

Share

Scientific paper by NutriLeads shows that its plant-based RG-I food ingredients support immune function and modulate the microbiota

25 March 2021

  • First scientific data showing immune supportive properties of plant-based RG-I derived from bell pepper and carrot
  • Study published in the “Nutrition, Immunity and Viral infection” special issue of the peer-reviewed journal, Nutrients
  • Immune health is a top priority for today’s consumers with six in ten people looking for functional foods and beverages to support their immunity [1]

Dutch health ingredients innovator, NutriLeads, announces the first peer-reviewed publication of data proving the immune modulating properties of its proprietary pectin-derived rhamnogalacturonan-I (RG-I) polysaccharides in the journal Nutrients.[2]

RG-I are natural, plant-derived compounds (polysaccharides), that interact with the gut bacteria (microbiota) and the host innate immune system. In selected traditional plant extracts, such pectic polysaccharides have previously been shown to have immunostimulatory effects. However, these traditional remedies are often expensive, derived from non-renewable sources, and could face regulatory challenges.

In this recent publication, NutriLeads shows that RG-I can be extracted from affordable and renewable crops, namely carrots and bell peppers, and even obtained from side streams of crop processing, allowing for sustainable and scalable production. RG-I from both carrot and bell pepper showed immune stimulating and microbiota modulating activity in vitro. Furthermore, bell pepper RG-I was shown to enhance innate immune responsiveness in a proof-of-concept trial in humans.

Commenting on the publication and the expected impact of the findings, Ruud Albers, PhD, CEO of NutriLeads, said: “We are delighted to share these new data, demonstrating the immunomodulatory effects of plant-based RG-I, which have the potential to bring health benefits to us all. We are particularly pleased that we can successfully derive RG-I from sustainable and widely available sources.

Due to the pandemic, immune health is even higher on the agenda than ever before, and we believe that this research shows that dietary supplementation with RG-I from specific food crops is ideally suited to support immune function and modulate the microbiota. We are well advanced with generating additional evidence showing the immune benefits of carrot-derived RG-I and are working together with Food and Food Supplement companies to deliver these benefits to consumers in the second half of 2021.”

Demand for food supplements and food and beverage products with immune health properties has been growing sharply in recent years. The global immune health supplements market alone was estimated to be worth USD 16.32 billion in 2019 and is expected to reach USD 29.40 billion by 2027.[3] In addition, recent research shows that 64% of respondents will aim to improve their immunity in the next 12 months.[4]

NutriLeads’ lead ingredient, BeniCaros, extracted from carrot pomace (a side stream from carrot juice production), has been developed to support immune function. This ingredient is expected to be available in the US for the formulation of dietary supplements and functional foods in the second half of 2021.

References
1. Innova Consumer Survey 2020 – https://www.prnewswire.com/il/news-releases/innova-identifies-top-10-food-and-beverage-trends-to-accelerate-innovation-in-2021-301155638.html

2. Early access article available at: https://www.mdpi.com/2072-6643/13/3/963

3. https://www.globenewswire.com/news-release/2020/10/27/2115103/0/en/Immune-Health-Supplements-Market-Worth-USD-29-40-Billion-at-7-4-CAGR-Rapid-Changes-in-Lifestyles-to-Bolster-Growth-says-Fortune-Business-Insights.html

4.  FMCG Gurus, Top Ten Trends for 2021, Dec 2020. https://fmcggurus.com/webinar-top-ten-trends-2021/

Share

NutriLeads attracts Series B funding to launch its innovative immune-enhancing ingredient, Xtramune™, and to progress its portfolio of health ingredients

3 September, 2020

Dutch Health Ingredients company, NUTRILEADS BV, announces the closing of a Series B financing round of 6.5 m€, led by ICOS CAPITAL together with GOEIE-GRUTTEN and existing shareholders DSM VENTURING, OOST NL, SHIFT INVEST and THUJA.

NutriLeads, established in 2012, develops innovative natural food ingredients with clinically proven health benefits for application in dietary supplements and functional foods. Its proprietary lead ingredient, XtramuneTM, is a unique carrot-derived fibre supporting immune function and resistance to respiratory infections.

This series B funding round marks a new phase for the company. Together with global partners in the food and supplement industry, NutriLeads will be driving XtramuneTM towards commercialization in 2021. In addition, two other ingredients from its portfolio, targeting gut health and metabolic health, will be progressed to proof of concept in humans.

Ruud Albers, CEO of NutriLeads indicates: “We are very excited about this successful funding round which helps to propel NutriLeads forward. People can strengthen their health with nutrition. It is our ambition to unlock the potential of clinically proven food ingredients and this funding round supports that mission. It is great to see that all our investors are committed to this shared goal.”

Nityen Lal, Managing Director of ICOS Capital Management BV: “Health ingredients are sought-after by food companies and their consumers. NutriLeads has impressed us by its professionalism, the quality of the work done and their network in the industry. We are confident that this is a worthwhile investment both for our LPs as well as for the consumers who will benefit from the health ingredients to be marketed.”

Share

NutriLeads wins funding for top-class innovators from European Innovation Council

March 29th, 2018, Wageningen, The Netherlands.

NutriLeads, a Dutch Health Ingredients company announces that its NUTRI-NEED project has been selected for €2.5 million funding under the EIC Accelerator (SME Instrument (phase 2) which is part of the European Innovation Council. The aim of the 2-year project is to prepare NutriLeads’ health promoting food ingredient Xtramune™ for commercialization.

NutriLeads’ most advanced product, Xtramune™, is a unique proprietary carrot-derived fibre under development to support immune function and improve resistance to respiratory infections. It has been successfully tested in preclinical models and in a proof of concept study in healthy volunteers. It is currently being studied in a clinical trial to assess its protective effect against an experimental common cold infection.

Ruud Albers, NutriLeads’ CEO comments: “The NUTRI-NEED project will accelerate the development of our food ingredient Xtramune™ and specifically it will allow NutriLeads to further scale-up the production process, obtain market access for Europe, perform a large clinical study in older adults (65+) with increased infection risk and prepare Xtramune™ for commercialization.”

The international jury of investors, entrepreneurs and business experts involved in the assessment of the proposals commented on the NUTRI-NEED project: “The idea, if successful, has huge potential to disrupt the market. It also has the potential to enhance Europe’s standing in the health supplement market vis a vis the United States. The IPR strategy is strong and well-implemented. The project has a very impressive team coming from the big players in the industry. They are experts in diverse fields that complement each other within the team.”

 

Share

Nutrileads, Nizo food research and Friesland Campina win EFRO grant

June 7th, 2017, Wageningen, The Netherlands.

NUTRILEADS B.V., a Dutch Nutrition & Health startup, together with NIZO food research (consortium leader) and Friesland Campina, has been awarded a €3,7 million EFRO project called CHALLENGE. The aims of the project are to develop new food ingredients that will support resistance to infections, as well as affordable and predictive research models in humans (Human Challenge Models).

NutriLeads develops supportive nutritional ingredients for application in dietary supplements, medical food and functional food products intended for specific target populations seeking to support their health. Its lead ingredient aims to support immune function and increase resistance to common infectious diseases such as colds and flu.

Ruud Albers, CEO of Nutrileads, has always been a strong believer and long-time advocate of the Human Challenge Model concept, in which the response of human volunteers to physiological challenges is assessed. According to Albers, the CHALLENGE consortium is a logical next step in substantiating the immune supportive effect of Nutrileads’ lead ingredient, a novel Immune Modulating Plant Polysaccharide.

Alwine Kardinaal, project leader and working at NIZO, says “the combined research power of the companies involved is quite unique and will enable us to take the next step in predicting health benefits with the use of Human Challenge Studies”.

The CHALLENGE project will be co-financed by the European Union and EFRO OP-Oost.

Share

Nutrileads closes series A round to advance the development of its lead nutritional ingredient supporting immune function

March 29th, 2017, Wageningen, The Netherlands.

Dutch nutritional health ingredients startup NUTRILEADS B.V. today announces the successful closing of a Series A financing round with existing shareholders DSM VENTURING, PPM OOST, SHIFT INVEST and THUJA CAPITAL.

NutriLeads develops supportive nutritional ingredients for application in dietary supplements, medical food and functional food products intended for specific target populations seeking to support their immune function. Its lead ingredient aims to support immune function and increase resistance to common infectious diseases such as colds and flu.

A proof of concept study in human volunteers showed an excellent tolerability and safety profile. More importantly, a dose dependent effect regarding the enhancement of immune function was demonstrated. In addition to these positive clinical results, a recent production pilot showed the feasibility of a cost-effective and sustainable production process for its lead ingredient.

The current Series A financing will be used to support the further development of NutriLead’s lead ingredient, a novel Immune Modulating Plant Polysaccharide. During the next phase, production will be scaled up and two human clinical trials to substantiate the immune supportive effect in different target populations will be performed.

The current investment supports the fast track development of our lead ingredient for application in dietary supplements, medical foods and functional foods. We are confident that this will help us realize our ambition to partner with ingredient suppliers and food companies to bring the benefits of our health ingredients to patients and consumers” indicates Ruud Albers, PhD, CEO of NutriLeads.

Share

Nutrileads announces positive outcome proof of concept study in humans

November 24th, 2016, Wageningen, The Netherlands.

NUTRILEADS B.V., a Dutch Nutrition & Health startup today announces the positive outcome of a proof of concept study in humans demonstrating that its lead ingredient IMPP-1 is safe, well tolerated and supports immune function in humans.

NUTRILEADS develops nutritional ingredients for application in health-promoting food products. The company was founded in 2012 based upon an invention originating from Unilever. In 2015, NutriLeads closed a successful seed financing round with an investor syndicate comprising Thuja Capital, DSM Venturing BV, PPM Oost and Shift Invest and is currently discussing aseries A financing.

NutriLeads’ lead ingredient Immuno Modulatory Plant Polysaccharide-1 (IMPP-1) can be sustainably sourced from food crops. Nutrileads is developing this patented ingredient for different food applications including dietary supplements, medical food and functional food to reach various target populations.

The results of the first proof of concept study with IMPP-1 in healthy volunteers were evaluated by an international group of key opinion leaders from industry and academia. The experts concluded that the results demonstrate excellent tolerability and safety characteristics and significant and dose dependent stimulation of the immune system.

The positive result in first proof of concept study in healthy volunteers provides the necessary confidence to go full speed ahead with our ambitious development program including several clinical trials to support the use of this proprietary ingredient from sustainable sources as dietary supplement and for application in specialized functional and medical food products” indicates Ruud Albers, PhD, CEO of NutriLeads.

Share

Nutrileads wins prestigious eurostars grant

November 21st, 2016, Wageningen, The Netherlands.

NUTRILEADS B.V., a Dutch Nutrition & Health startup has won a prestigious Eurostars grant to support the development of its lead ingredient IMPP-1 for application in medical foods.

Nutrileads (as consortium leader) and 4 partners from the Netherlands, Germany and Finland have been awarded a € 2 million Eurostars project called NIMF. The consortium will develop Nutrileads’ proprietary ingredient Immune Modulatory Plant Polysaccharide-1 (IMPP-1) into a new ingredient for medical food products to fight impaired immune functioning as a result of malnutrition (particularly common in a variety of patient groups). Nutrileads is developing this ingredient, in addition to medical food products, also for other food applications like dietary supplements and functional food.

The NIMF project was the highest rated project with a Dutch participant, ranking 4th of 269 applications across all fields in Europe. Erik Dam, CBO of NutriLeads emphasizes: “The very positive evaluation of the NIMF project provides a further validation of the relevance of our proposition and the quality of our science, team and partners”.

Share